Volume | 252,208 |
|
|||||
News | - | ||||||
Day High | 78.625 | Low High |
|||||
Day Low | 78.00 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Alcon Inc | ALC | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
78.36 | 78.00 | 78.625 | 79.57 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
3,919 | 252,208 | US$ 78.37 | US$ 19,766,468 | - | 69.44 - 88.2312 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
10:46:49 | 100 | US$ 78.525 | USD |
Alcon Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
27.06B | 499.70M | - | 9.46B | 974M | 1.95 | 27.78 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alcon News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALC Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 79.09 | 81.43 | 78.00 | 79.77 | 828,100 | -0.565 | -0.71% |
1 Month | 82.88 | 84.96 | 78.00 | 81.64 | 854,243 | -4.35 | -5.25% |
3 Months | 75.29 | 88.2312 | 74.30 | 82.22 | 909,308 | 3.24 | 4.30% |
6 Months | 72.12 | 88.2312 | 69.44 | 78.21 | 878,490 | 6.41 | 8.88% |
1 Year | 72.83 | 88.2312 | 69.44 | 78.73 | 818,284 | 5.70 | 7.82% |
3 Years | 75.98 | 88.78 | 55.21 | 74.23 | 859,602 | 2.55 | 3.35% |
5 Years | 57.60 | 88.78 | 39.37 | 67.35 | 975,624 | 20.93 | 36.33% |
Alcon Description
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |